EX-16.1 2 apgn-ex16_1.htm EX-16.1 EX-16.1

 


Exhibit 16.1

 

 

 

November 14, 2022

 

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

 

 

Commissioners:

 

We have read the statements made by Apexigen, Inc. (formerly known as Brookline Capital Acquisition Corp.) under Item 4.01 of its Form 8-K dated November 8, 2022. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Apexigen, Inc. contained therein.

 

Very truly yours,

 

/s/ Marcum llp

 

Marcum llp